Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment.

@article{Peters1995PegaspargaseVA,
  title={Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment.},
  author={Byron G Peters and Bryon Goeckner and John J Ponzillo and William S. Velasquez and A. L. Wilson},
  journal={Formulary},
  year={1995},
  volume={30 7},
  pages={
          388-93
        }
}
Asparaginase is an effective treatment for patients with acute lymphocytic leukemia (ALL). Unfortunately, asparaginase therapy is associated with a high incidence of hypersensitivity reactions (up to 73%), including life-threatening anaphylaxis, and its half-life of approximately 20 hours necessitates daily administration. Pegaspargase, a modification of L-asparaginase, has a longer half-life (357 hours), a decreased incidence of hypersensitivity reactions, and when doses every 14 days… CONTINUE READING

References

Publications referenced by this paper.

Pegaspargase versus asparaginase in adult ALL : a pharmacoeconomic assessment

L. WilsonA
-1